CN103417763A - Medicinal composition for treating osteoporosis and preparation method and application of medicinal composition - Google Patents
Medicinal composition for treating osteoporosis and preparation method and application of medicinal composition Download PDFInfo
- Publication number
- CN103417763A CN103417763A CN2013102967166A CN201310296716A CN103417763A CN 103417763 A CN103417763 A CN 103417763A CN 2013102967166 A CN2013102967166 A CN 2013102967166A CN 201310296716 A CN201310296716 A CN 201310296716A CN 103417763 A CN103417763 A CN 103417763A
- Authority
- CN
- China
- Prior art keywords
- weight
- herba epimedii
- extract
- pharmaceutical composition
- rhizoma alismatis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention belongs to the technical field of traditional Chinese medicine, and particularly provides a medicinal composition for treating osteoporosis. The medicinal raw materials of the medicinal composition comprise rhizome of oriental water plantain, herba epimedii and pawpaw, and the weight ratio range is as follows: 5 to 40 parts of rhizome of oriental water plantain, 10 to 30 parts of herba epimedii and 10 to 30 parts of pawpaw. The invention further provides a preparation method and specific application of the medicinal composition. Proved by a pharmacological experiment, the medicinal composition can enhance the bone mineral density of an osteoporotic model rat, obviously alleviates symptoms relevant to the osteoporosis, and has a better treating effect on the osteoporosis.
Description
Technical field
The present invention relates to a kind of osteoporotic pharmaceutical composition for the treatment of, especially relate to a kind of osteoporotic Chinese medicine composition and its production and use for the treatment of, belong to technical field of Chinese medicines.
Background technology
Osteoporosis is impaired with the osseous tissue microstructure, and bone ore deposit composition and bone matrix equal proportion ground constantly reduce, the sclerotin attenuation, and bone trabecula quantity reduces, the disease of a kind of general bone metabolism obstacle that the increase of bone fragility and risk of fractures degree raise.Osteoporosis is divided into primary osteoporosis and the large class of secondary osteoporosis two.Primary osteoporosis is divided into again three kinds of postmenopausal osteoporosis (I type), senile osteoporosis (II type) and idiopathic osteoporosises (comprising juvenile).Postmenopausal osteoporosis generally occurs in after postmenopausal women in 5-10, and senile osteoporosis refers generally to the osteoporosis that the old man occurs in 70 years old afterwards, and idiopathic osteoporosis mainly occurs in teenager.Osteoporosis, also may be caused by various diseases with menopause and old relevant primary osteoporosis except mainly, be called secondary osteoporosis.
Osteoporosis can cause bone strength to weaken and the incidence rate of fracturing increases, fracture is the complication that osteoporosis is common and the most serious, be apt to occur in the positions such as hip, distal radius and spinal column, not only had a strong impact on old people's healthy and quality of life, but also be that the old people is disabled, lethal one of the main reasons.Add up according to investigations osteoporosis of female later to 80 years old at 50 years old, its sickness rate increases to more than 80%, 80 years old up to 70% by 20%.Osteoporosis and complication thereof are to cause the senior health and fitness to be undermined one of dead major reason.Due to being widely current and hazardness of osteoporosis, primary osteoporosis has become China and even global public health problem at present, to osteoporotic control, has become modern medicine important topic urgently to be resolved hurrily.
Often select on the market at present bisphosphonates (as fosamax, Zoledronic Acid, risedronate sodium), calcitonin class and estrogens medicine to be treated, but these drug side effectes are larger, make to have brought certain restriction in the selection of medicine, at present the Chinese medicine Mechanism Study of osteoporosis and the research of Therapeutic Method have been had to certain progress, Therapeutic Method substantially can be divided into the kidney invigorating warming YANG, nourishing YIN for benefiting the kidney, invigorating the spleen and replenishing QI, qi and blood tonifying, strengthening the tendons and bones, promoting blood circulation and stopping pain etc., and to person in middle and old age and menopause the patient there is good curative effect.Existing many research shows, the kidney invigorating can Psoralen, can promote the healing of fracture by the kidney invigorating, prevents hyperosteogeny and osteoporosis, reduces the pathological changes of bone.Usually select clinically now commercially available Chinese patent medicine GUSONGBAO KELI to carry out symptomatic treatment, obtained clinical efficacy preferably, this Chinese patent medicine formula is comprised of Herba Epimedii, Radix Dipsaci, the Rhizoma Anemarrhenae, Radix Rehmanniae, Rhizoma Sparganii, Rhizoma Curcumae, Rhizoma Chuanxiong, Radix Paeoniae Rubra and Concha Ostreae.Chinese patent 201210148462.9 discloses the osteoporotic medicine of a kind of control, and this medicine is comprised of Rhizoma Drynariae 10-20 part, Calyx seu Fructus physalis 20-30 part, Flos Carthami 10-30 part, Fructus Cnidii 20-50 part, Rhizoma Chuanxiong 5-15 part, Rhizoma Homalomenae 5-15 part, Radix Achyranthis Bidentatae 5-10 part, Fructus Ligustri Lucidi 10-20 part and Rhizoma Polygoni Cuspidati 10-20 part.Patent 200910093707.0 discloses a kind of osteoporotic Chinese medicine for the treatment of, and this Chinese medicine is comprised of Cortex Eucommiae 4-30 part, Radix Angelicae Sinensis 4-30 part, Radix Notoginseng 3-20 part, Radix Rehmanniae Preparata 5-40 part, Ganoderma 2-12 part, Fructus Corni 4-30 part and Radix Achyranthis Bidentatae 4-30 part.Patent 201210508232.9 discloses a kind of osteoporotic Chinese medicine for the treatment of, and this Chinese medicine is comprised of Radix Astragali 6-10, Fructus Schisandrae Chinensis 8-12, Fructus Aurantii Immaturus 6-10, Herba Epimedii 4-8, Radix Cyathulae 6-10, Squama Manis 8-12, Semen Cuscutae 4-8, Caulis Spatholobi 13-17, Radix Polygoni Multiflori Preparata 8-12, only angle cattle 6-10, gravelstone pine 4-8, Lignum Acronychiae 13-17, Semen Trigonellae 8-12, Flos Rosae Rugosae 1-5, Rhizoma Drynariae 13-17.Although above-mentioned patented technology has curative effect in various degree to osteoporosis, because its flavour of a drug are many, formula is complicated, and consumption of raw materials is large, is difficult to control product quality when industrialization is produced, and keeps product stable.
Summary of the invention
The object of the invention is to solve the deficiencies in the prior art, a kind of osteoporotic pharmaceutical composition for the treatment of is provided, the proportioning of this pharmaceutical composition can improve the therapeutical effect of Rhizoma Alismatis, Herba Epimedii and Fructus Chaenomelis three herbal medicines and play the effect of Synergistic.This pharmaceutical composition is comprised of following raw material and weight ratio: Rhizoma Alismatis 5-40 weight portion, Herba Epimedii 10-30 weight portion, Fructus Chaenomelis 10-30 weight portion; Preferably, Rhizoma Alismatis 10-35 weight portion, Herba Epimedii 15-25 weight portion, Fructus Chaenomelis 15-25 weight portion; Preferably, Rhizoma Alismatis 15-30 weight portion, Herba Epimedii 20 weight portions, Fructus Chaenomelis 20 weight portions; Preferably, Rhizoma Alismatis 30 weight portions, Herba Epimedii 20 weight portions, Fructus Chaenomelis 20 weight portions; Preferably, Rhizoma Alismatis 25 weight portions, Herba Epimedii 20 weight portions, Fructus Chaenomelis 20 weight portions.
Treatment of the present invention is treated osteoporotic pharmaceutical composition except the form fed intake with Herba Epimedii, Rhizoma Alismatis, Fructus Chaenomelis crude drug, can also adopt the form fed intake with Herba Epimedii, Rhizoma Alismatis, Fructus Chaenomelis (effective site), therefore the present invention further discloses a kind of osteoporotic extract pharmaceutical composition for the treatment of, the raw material of this pharmaceutical composition consists of: Rhizoma Alismatis extract 5-40 weight portion, Herba Epimedii extract 10-30 weight portion, Fructus Chaenomelis extract 10-30 weight portion; Preferably, Rhizoma Alismatis extract 30 weight portions, Herba Epimedii extract 20 weight portions, Fructus Chaenomelis extract 20 weight portions.
The present invention also aims to provide a kind of pharmaceutical composition preparation method of the present invention for preparing, it comprises the following steps:
S1: by component and weight ratio, take raw material;
S2: by after the raw material mix homogeneously, add pharmaceutically acceptable adjuvant to be prepared into pharmaceutical preparation pharmaceutically commonly used.
Pharmaceutical composition of the present invention can be prepared into according to the conventional method of pharmaceutical field the above dosage form of any pharmaceutics; Pharmaceutical composition can be applied to the patient by modes such as oral, suction or intestinal external administrations.
Described pharmaceutically types of drug preparations commonly used comprises: the tablet used during oral administration, effervescent tablet, capsule, pill, powder, granule, syrup, oral liquid etc.; The freeze-dried powder used when the intestinal external administration and injection etc.
This pharmaceutical composition is for the purposes at preparation treatment medicine for treating osteoporosis.
For above-mentioned dosage form can be realized, need when these dosage forms of preparation, add the acceptable adjuvant of pharmacy, such as: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, acetic acid chloroethene are determined, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods; Substrate comprises: insect wax etc.
The preparation of Rhizoma Alismatis extract: the weighting raw materials Rhizoma Alismatis, with 70%-95% alcoholic solution reflux, extract, 3 times, each 1-2h, filter, merging filtrate, concentrating under reduced pressure obtains thick extractum, after spray-dried extract powder make Rhizoma Alismatis extract.
The preparation of Herba Epimedii extract: the weighting raw materials Herba Epimedii, with 70%-95% alcoholic solution reflux, extract, 3 times, each 1-2h, filter, merging filtrate, concentrating under reduced pressure obtains thick extractum, after spray-dried extract powder make the Herba Epimedii extract.
The preparation of Fructus Chaenomelis extract: the weighting raw materials Rhizoma Anemarrhenae, with 70%-95% alcoholic solution reflux, extract, 3 times, each 1-2h, filter, merging filtrate, concentrating under reduced pressure obtains thick extractum, after spray-dried extract powder make Rhizoma Anemarrhenae extract.
Rhizoma Alismatis extract of the present invention, Herba Epimedii extract and Fructus Chaenomelis extract, it prepares extracting method and can select alcohol reflux, soak conventional any one method extraction such as extraction, supersound extraction or percolation extraction; Further, crude drug also can purified, refinement treatment after extracting, as crossed macroporous resin column.
Herba Epimedii of the present invention is Berberidaceae plant Epimedium brevicornum, has kidney-replenishing, bone and muscle strengthening, the effect of wind-damp dispelling; Rhizoma Alismatis is Notes On Alism At Aceae, the effect that there is diuretic, eliminating dampness by diuresis, expels the heat-evil, for edema, dysuria, phlegm retention, have loose bowels, damp-heat vaginal discharge, stranguria with turbid discharge etc.; Fructus Chaenomelis is the Rosaceae Fructus Chaenomelis, has relaxing muscles and tendons and activating QI and blood in the collateral, and the merit of dehumidifying stomach function regulating, for rheumatic arthralgia, the contracture of muscle arteries and veins, beriberi swells and ache and vomit and diarrhoea convulsion.
Pharmaceutical composition of the present invention through the beneficial effect of pharmacodynamics checking is:
Index of correlation improvement effect to the osteoporosis model rat when Herba Epimedii, Rhizoma Alismatis and Fructus Chaenomelis are applied separately under the same dose condition is not obvious, osteoporosis is not had to obvious therapeutical effect, Herba Epimedii, Rhizoma Alismatis and Fructus Chaenomelis are carried out after compatible combination to the index of correlation improvement effect of osteoporosis model rat in ratio of the present invention, osteoporosis is had to obvious therapeutical effect, and then explanation Herba Epimedii, Rhizoma Alismatis and Fructus Chaenomelis carry out after compatible combination having the effect of Synergistic by ratio of the present invention.It is the most obvious that the present invention extracts the therapeutical effect of object height, middle dosage group, has equal therapeutic effect with GUSONGBAO KELI, for clinical application provides a kind of new selection.
The specific embodiment
Below in conjunction with specific embodiment, technical scheme of the present invention is described in further detail, but protection scope of the present invention is not limited to the following stated.
Embodiment 1
Take raw material Rhizoma Alismatis 5kg, Herba Epimedii 10kg, Fructus Chaenomelis 10kg, add adjuvant to be prepared into tablet according to the common process method.
Embodiment 2
Take raw material Rhizoma Alismatis 10kg, Herba Epimedii 15kg, Fructus Chaenomelis 15kg, add adjuvant to be prepared into tablet according to the common process method.
Embodiment 3
Take raw material Rhizoma Alismatis 15kg, Herba Epimedii 20kg, Fructus Chaenomelis 20kg, add adjuvant to be prepared into tablet according to the common process method.
Embodiment 4
Take raw material Rhizoma Alismatis 20kg, Herba Epimedii 20kg, Fructus Chaenomelis 20kg, add adjuvant to be prepared into tablet according to the common process method.
Embodiment 5
Take raw material Rhizoma Alismatis 25kg, Herba Epimedii 20kg, Fructus Chaenomelis 20kg, add adjuvant to be prepared into granule according to the common process method.
Embodiment 6
Take raw material Rhizoma Alismatis 30kg, Herba Epimedii 20kg, Fructus Chaenomelis 20kg, add adjuvant to be prepared into granule according to the common process method.
Embodiment 7
Take raw material Rhizoma Alismatis 35kg, Herba Epimedii 25kg, Fructus Chaenomelis 25kg, add adjuvant to be prepared into capsule according to the common process method.
Embodiment 8
Take raw material Rhizoma Alismatis 40kg, Herba Epimedii 30kg, Fructus Chaenomelis 30kg, add adjuvant to be prepared into capsule according to the common process method.
Embodiment 9
Take raw material Rhizoma Alismatis extract 5kg, Herba Epimedii extract 10kg, Fructus Chaenomelis extract 10kg, add adjuvant to be prepared into tablet according to the common process method.
Embodiment 10
Take raw material Rhizoma Alismatis extract 15kg, Herba Epimedii extract 20kg, Fructus Chaenomelis extract 20kg, add adjuvant to be prepared into tablet according to the common process method.
Embodiment 11
Take raw material Rhizoma Alismatis extract 30kg, Herba Epimedii extract 20kg, Fructus Chaenomelis extract 20kg, add adjuvant to be prepared into granule according to the common process method.
Embodiment 12
Take raw material Rhizoma Alismatis extract 35kg, Herba Epimedii extract 25kg, Fructus Chaenomelis extract 25kg, add adjuvant to be prepared into capsule according to the common process method.
Embodiment 13
Take raw material Rhizoma Alismatis extract 40kg, Herba Epimedii extract 30kg, Fructus Chaenomelis extract 30kg, add adjuvant to be prepared into capsule according to the common process method.
Prove beneficial effect of the present invention below by concrete pharmacy test:
One, the test of medicine antagonism model rat with osteoporosis of the present invention
1 experiment material
1.1 laboratory animal
Femalely do not educate 120 of SPF level SD rats, body weight 200 ± 20g, provide by Sichuan Academy of Medical Sciences institute of lab animals, animal credit number: SCXK (river) 2009-23, at room temperature 22-24 ℃, under light and shade cycle 12h/12h condition, raise, freely drink water and ingest.
1.2 Experimental agents
Pharmaceutical composition: Rhizoma Alismatis 3kg, Herba Epimedii 2kg, Fructus Chaenomelis 2kg, boil 1 hour with 8 times of decoctings, extract 2 times, collecting decoction, filter the gained medicinal liquid with double gauze, be condensed into the medicinal liquid of 0.5g/ml, 4 ℃ save backup, being the pharmaceutical composition high dose (gets the part medicinal liquid and adds same volume normal saline, mix, be dosage in compositions; Therefrom the dosage group is got the part medicinal liquid and is added same volume normal saline again, mixes, and is the compositions low dosage).
GUSONGBAO KELI, produced authentication code: the accurate word Z52020005 of traditional Chinese medicines, lot number: 20111223 by Fuhua Pharmaceutical LLC, Guizhou.
The extract group: take raw material Rhizoma Alismatis extract 300g, Herba Epimedii extract 200g, Fructus Chaenomelis extract 200g, add distilled water to be mixed with the medicinal liquid of 0.5g/ml after evenly mixing, and 4 ℃ save backup.(get the part medicinal liquid and add same volume normal saline, mix, be dosage in extract; Therefrom the dosage group is got the part medicinal liquid and is added same volume normal saline again, mixes, and is the extract low dose group).
The Herba Epimedii group: the 2kg Herba Epimedii boils 1 hour with 8 times of decoctings, extracts 2 times, and collecting decoction, filter the gained medicinal liquid with double gauze, be condensed into the medicinal liquid of 0.5g/ml, and 4 ℃ save backup.
Rhizoma Alismatis group: 2kg boils 1 hour with 8 times of decoctings, extracts 2 times, and collecting decoction, filter the gained medicinal liquid with double gauze, be condensed into the medicinal liquid of 0.5g/ml, and 4 ℃ save backup.
Fructus Chaenomelis group: 2kg boils 1 hour with 8 times of decoctings, extracts 2 times, and collecting decoction, filter the gained medicinal liquid with double gauze, be condensed into the medicinal liquid of 0.5g/ml, and 4 ℃ save backup.
1.3 animal model
At first press 300mg/kg intraperitoneal injection of anesthesia rat with the 100g/L chloral hydrate, by median abdominal incision, the laggard abdomen of blunt separation abdominal muscle peritoneum, find ovary by it excision, sews up the incision, and within postoperative 1 week, takes out stitches.
1.4 experimental technique and grouping
It is 12 groups that this experiment is divided into, 10 every group, i.e. and Normal group, model control group, the high, medium and low dosage group of compositions, GUSONGBAO KELI group, the high, medium and low dosage group of extract, Herba Epimedii group, Rhizoma Alismatis group and Fructus Chaenomelis group.Normal group: according to normal diet, do not do any special handling.The anesthesia of model group, operation pathway be the same modeling method all, spay, and after postoperative one week, gavage gives the normal saline of 2ml/ days, once a day, continuous 3 months.The anesthesia of all the other each treatment groups, the same modeling method of operation pathway, spay, after postoperative one week, gavage gives the medicinal liquid of dosage 2ml/ days, once a day, continuous 3 months.Do not limit feedstuff and water during postoperative and administration, 3 months after operation is the laboratory observation phase.
2 laboratory observation indexs
Bone density: after gavage finishes, by each group rat anesthesia, with the dual-energy x-ray borne densitometers, measure and respectively organize the rat body bone density.
Serum calcium, phosphorus detection: after experiment finishes, water and chloralization rat, adopt the carotid duct drain to get serum standby, isolate serum to be measured, wherein blood calcium determination adopts methylthymol blue (MTB) method, serium inorganic phosphorus is measured and is adopted the molybdic acid method, and concrete operation step is undertaken by the test kit description.
The serum alkaline phosphatase assay: use the 4-NPP method, concrete operation step is undertaken by the test kit description.
3 statistical procedures
Application SPSS15.0 statistical software carries out data statistics processing.
4. result
4.1 the impact on the experimental rat bone density
The impact of table 1 on the experimental rat bone density
Annotate: with Normal group, compare,
▲P<0.05; Compare * P<0.05 with model group
As shown in Table 1, with respect to Normal group, the thigh of model group rat, spinal column and Whole Body Bone Scanning density all have decline (p<0.05) in various degree, show obvious osteoporosis and change.With respect to model control group, the high, medium and low dosage group of pharmaceutical composition, the high, medium and low dosage group of extract, GUSONGBAO KELI group to thigh, spinal column and the Whole Body Bone Scanning density of rat all have in various degree increase effect (p<0.05), showing has therapeutical effect to osteoporosis, wherein extracts object height, the effect of middle dosage group is the most obvious.Herba Epimedii group, Rhizoma Alismatis group and Fructus Chaenomelis group have rising trend to thigh, spinal column and the Whole Body Bone Scanning density of rat, but not statistically significant.
4.2 the impact on experimental rat serum osteocalcin, calcium, phosphorus
The impact of table 2 on experimental rat serum osteocalcin, calcium, phosphorus
Annotate: with Normal group, compare,
▲P<0.05; Compare * P<0.05 with model group
As shown in Table 2, with respect to Normal group, the content of model group rat blood serum Bone Gla protein, calcium, phosphorus all descends.With respect to model control group, the high, medium and low dosage group of pharmaceutical composition, the high, medium and low dosage group of extract, GUSONGBAO KELI group all can be in various degree rising rat blood serum Bone Gla protein, calcium, the content (p<0.05) of phosphorus, wherein extract object height, the effect of middle dosage group is the most obvious.Herba Epimedii group, Rhizoma Alismatis group and Fructus Chaenomelis group have certain rising trend to the content of rat blood serum Bone Gla protein, calcium, phosphorus, but act on not obvious, not statistically significant.
Above-mentioned experimental result shows, under the same dose condition, the independent application of Herba Epimedii, Rhizoma Alismatis and Fructus Chaenomelis is not obvious to the index of correlation improvement effect of osteoporosis model rat, osteoporosis is not had to obvious therapeutical effect, Herba Epimedii, Rhizoma Alismatis and Fructus Chaenomelis are carried out after compatible combination to the index of correlation improvement effect of osteoporosis model rat in ratio of the present invention, osteoporosis is had to obvious therapeutical effect, and then explanation Herba Epimedii, Rhizoma Alismatis and Fructus Chaenomelis carry out after compatible combination having the effect of Synergistic by ratio of the present invention.It is the most obvious that the present invention extracts the therapeutical effect of object height, middle dosage group, with GUSONGBAO KELI, has equal therapeutic effect.
Two, the determination test of medicine of the present invention to the mice pain threshold value
1 experiment material
1.1 laboratory animal
110 of female kunming mices, body weight 20 ± 2g, provide by Sichuan Academy of Medical Sciences institute of lab animals, and animal credit number: SCXK (river) 2010-12, at room temperature 22-24 ℃, raises under light and shade cycle 12h/12h condition, freely drinks water and ingests.
1.2 Experimental agents and grouping
It is 11 groups that this experiment is divided into, 10 every group, i.e. and Normal group, the high, medium and low dosage group of compositions, GUSONGBAO KELI group, the high, medium and low dosage group of extract, Herba Epimedii group, Rhizoma Alismatis group and Fructus Chaenomelis group.The above-mentioned medicine of respectively organizing is converted into to the crude drug dosage gastric infusion of mice consumption 2.5g/kg/d according to adult's dosage, each gavage 0.2ml, blank group gavage gives the normal saline of same dose.
1.3 animal model and test method
Water-bath is added to suitable quantity of water, water temperature is controlled at (55 ± 0.5) ℃, get the glass beaker of 1000ml, its bottom surface is fully contacted with water in water-bath, be fixed, preheating 10min, get one of mice at every turn and be put in beaker, and the pain threshold (s) that the sufficient time is designated as this Mus appears licking in mice.All pain thresholds be less than 5s be greater than 50s or in beaker often the leaper all give it up.Measure the normal pain threshold of every mice before administration, after administration, 30min surveys the variation of its pain threshold again.Pain threshold is greater than 60s and remembers with 60s.
2 laboratory observation indexs
Measure the variation of administration front and back pain threshold, calculate and improve pain threshold and pain threshold increase rate.Pain threshold (s) after pain threshold (s)-administration before raising pain threshold (s)=administration; Threshold of pain increase rate (%)=(improving the front pain threshold of pain threshold/administration) * 100%.
3 experimental results
Before and after the administration of blank group, pain threshold does not have significant change, and before and after all the other each treatment group medications, pain threshold has variation in various degree.The results are shown in Table 3.
Pain threshold situation of change before and after table 3 administration
Annotate: with comparison before medication, * P<0.05
Above-mentioned result of the test shows under the same dose condition, while applying Herba Epimedii, Rhizoma Alismatis and Fructus Chaenomelis separately, pain threshold before and after administration changes not obvious, can obviously improve the pain threshold of administration front and back after Herba Epimedii, Rhizoma Alismatis and Fructus Chaenomelis combination and compatibility, illustrate that pharmaceutical composition of the present invention has analgesic activity.Present composition senior middle school dosage group, the dosage group effect of extract senior middle school are the most obvious, and its analgesic activity is better than GUSONGBAO KELI.
Chinese patent medicine GUSONGBAO KELI formula is by Herba Epimedii, Radix Dipsaci, the Rhizoma Anemarrhenae, Radix Rehmanniae, Rhizoma Sparganii, Rhizoma Curcumae, Rhizoma Chuanxiong, Radix Paeoniae Rubra and Concha Ostreae form, pharmaceutical composition of the present invention is only by Herba Epimedii, Rhizoma Alismatis and Fructus Chaenomelis three flavor conventional medicines form, with existing similar treatment osteoporosis Chinese patent medicine, compare, ingredients of the present invention is simple, cheap, the whole medical material amount of using obviously reduces, and verify to have by experiment and treat preferably osteoporosis and analgesic clinical efficacy, the present invention provides new medication to select for clinical, the use amount of also having saved medical material simultaneously, reached and economized on resources, reduce the purpose of energy consumption.
Claims (10)
1. treat osteoporotic pharmaceutical composition for one kind, it is characterized in that: it is comprised of following raw material and weight ratio: Rhizoma Alismatis 5-40 weight portion, Herba Epimedii 10-30 weight portion, Fructus Chaenomelis 10-30 weight portion.
2. a kind of osteoporotic pharmaceutical composition for the treatment of according to claim 1, it is characterized in that: the ratio of weight and number of described each raw material is: Rhizoma Alismatis 10-35 weight portion, Herba Epimedii 15-25 weight portion, Fructus Chaenomelis 15-25 weight portion.
3. a kind of osteoporotic pharmaceutical composition for the treatment of according to claim 1, it is characterized in that: the ratio of weight and number of described each raw material is: Rhizoma Alismatis 15-30 weight portion, Herba Epimedii 20 weight portions, Fructus Chaenomelis 20 weight portions.
4. a kind of osteoporotic pharmaceutical composition for the treatment of according to claim 1, it is characterized in that: the ratio of weight and number of described each raw material is: Rhizoma Alismatis 30 weight portions, Herba Epimedii 20 weight portions, Fructus Chaenomelis 20 weight portions.
5. a kind of osteoporotic pharmaceutical composition for the treatment of according to claim 1, it is characterized in that: the ratio of weight and number of described each raw material is: Rhizoma Alismatis 25 weight portions, Herba Epimedii 20 weight portions, Fructus Chaenomelis 20 weight portions.
6. treat osteoporotic pharmaceutical composition for one kind, it is characterized in that: the ratio of weight and number of described each raw material is: Rhizoma Alismatis extract 5-40 weight portion, Herba Epimedii extract 10-30 weight portion, Fructus Chaenomelis extract 10-30 weight portion.
7. a kind of osteoporotic pharmaceutical composition for the treatment of according to claim 6, it is characterized in that: the ratio of weight and number of described each raw material is: Rhizoma Alismatis extract 30 weight portions, Herba Epimedii extract 20 weight portions, Fructus Chaenomelis extract 20 weight portions.
8. a method for preparing the osteoporotic pharmaceutical composition of the described treatment of any one claim in claim 1～7, it is characterized in that: it comprises the following steps:
S1: by component and weight ratio, take raw material;
S2: by after the raw material mix homogeneously, add pharmaceutically acceptable adjuvant to be prepared into pharmaceutical preparation pharmaceutically commonly used.
9. a kind of preparation method for the treatment of osteoporotic pharmaceutical composition according to claim 8, it is characterized in that: described pharmaceutical preparation is tablet, effervescent tablet, capsule, granule, pill, powder or oral liquid.
10. as the purposes of the described pharmaceutical composition of any one claim in claim 1～7 in preparation treatment medicine for treating osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310296716.6A CN103417763B (en) | 2013-07-16 | 2013-07-16 | One treats osteoporotic pharmaceutical composition and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310296716.6A CN103417763B (en) | 2013-07-16 | 2013-07-16 | One treats osteoporotic pharmaceutical composition and its production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103417763A true CN103417763A (en) | 2013-12-04 |
| CN103417763B CN103417763B (en) | 2015-09-09 |
Family
ID=49643503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310296716.6A Active CN103417763B (en) | 2013-07-16 | 2013-07-16 | One treats osteoporotic pharmaceutical composition and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103417763B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352718A (en) * | 2014-11-26 | 2015-02-18 | 湖南中医药大学 | Medicine for treating osteoporosis and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101690793B (en) * | 2009-08-28 | 2011-09-21 | 贵州百灵企业集团制药股份有限公司 | Method for detecting quality of bone strengthening capsules |
-
2013
- 2013-07-16 CN CN201310296716.6A patent/CN103417763B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101690793B (en) * | 2009-08-28 | 2011-09-21 | 贵州百灵企业集团制药股份有限公司 | Method for detecting quality of bone strengthening capsules |
Non-Patent Citations (1)
| Title |
|---|
| 彭丽红，等: "骨质疏松症的中医药治疗研究进展", 《西北药学杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352718A (en) * | 2014-11-26 | 2015-02-18 | 湖南中医药大学 | Medicine for treating osteoporosis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103417763B (en) | 2015-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101239112A (en) | Chinese medicinal composition for regulating blood fat and preparation thereof | |
| CN104138550A (en) | Preparation method of medicine for treating peptic ulcers | |
| CN104491052A (en) | Traditional Chinese medicine composition for treating rheumatic and rheumatoid arthritis and preparation method thereof | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN101874850B (en) | Medicament for treating chronic urticaria | |
| CN103394002B (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN104127683A (en) | Traditional Chinese medicine composition for treating or preventing female postmenopausal osteoporosis | |
| CN103417763B (en) | One treats osteoporotic pharmaceutical composition and its production and use | |
| CN104189781A (en) | Pharmaceutical composition for treating neuroglioma | |
| CN104027660A (en) | Traditional Chinese medicine preparation for treating urticaria | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| CN102008635A (en) | Traditional Chinese medicine preparation for treating acute pancreatitis | |
| CN103041362B (en) | Drug for treating rheumatism and rheumatoid and preparation method thereof | |
| CN102114070A (en) | Compound traditional Chinese medicine for treating osteoporosis and preparation method thereof | |
| CN105521332A (en) | Traditional Chinese medicinal composition for treating anal fissure, and preparation method and application thereof | |
| CN100367997C (en) | Medicine for treating arthrolithiasis and preparing method thereof | |
| CN102319423B (en) | Health care product for treating habitual constipation caused by internal heat due to yin deficiency | |
| CN102018849A (en) | Traditional Chinese medicine composition for preventing irregular menstruation and preparation method thereof | |
| CN104587251A (en) | Traditional Chinese medicine capsules for treating gout and preparation method thereof | |
| CN105250749A (en) | Traditional Chinese medicine for treating thyroid adenoma and preparation method thereof | |
| CN104208510A (en) | Medicine for treating chronic nephritis | |
| CN104367862A (en) | Traditional Chinese medicinal composition for treating urethral calculus | |
| CN103721110A (en) | Traditional Chinese medicinal prescription with health-care and weight reducing effects and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20171228 Address after: 100000 Beijing city in Haidian District Cuiwei Building No. 14 Patentee after: Beijing Beijing Intellectual Technology Co. Ltd. Address before: 266024 Shandong province Qingdao City, Ningxia Road No. 14 B three unit 301 Patentee before: Li Qingping |
|
| TR01 | Transfer of patent right |